News coverage about Opexa Therapeutics (NASDAQ:ACER) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Opexa Therapeutics earned a news impact score of 0.01 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 44.7837631552227 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Opexa Therapeutics (NASDAQ:ACER) opened at $13.50 on Tuesday. The company has a market capitalization of $99.46, a PE ratio of -2.35 and a beta of 2.26. Opexa Therapeutics has a 12-month low of $5.69 and a 12-month high of $22.63.

Opexa Therapeutics (NASDAQ:ACER) last released its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) EPS for the quarter. analysts expect that Opexa Therapeutics will post -1.48 earnings per share for the current fiscal year.

Several research firms recently commented on ACER. ValuEngine lowered Opexa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. HC Wainwright began coverage on Opexa Therapeutics in a research report on Wednesday, December 20th. They issued a “buy” rating for the company.

COPYRIGHT VIOLATION WARNING: “Opexa Therapeutics (ACER) Earns Media Sentiment Rating of 0.01” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at

Opexa Therapeutics Company Profile

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Insider Buying and Selling by Quarter for Opexa Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with's FREE daily email newsletter.